PDCD1 and neoplasm: Moreover, we detected an association between pre-therapy levels of tissue resident CD8+ T cell signature and better response to anti-PD-1 therapy, suggesting that anti-PD-1 immunotherapy may obtain a greater benefit in reducing both primary tumor and tumor thrombus with higher proportions of tissue resident CD8+ T cells.